Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.

Détails

Ressource 1Télécharger: 31205470_BIB_70A914BCFC4C.pdf (1240.44 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_70A914BCFC4C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
Périodique
Journal of oncology
Auteur⸱e⸱s
De Goycoechea D., Stalder G., Martins F., Duchosal M.A.
ISSN
1687-8450 (Print)
ISSN-L
1687-8450
Statut éditorial
Publié
Date de publication
2019
Peer-reviewed
Oui
Volume
2019
Pages
9513701
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Immune checkpoint inhibition (ICI) became one of the major breakthroughs in cancer treatment over the past decade and entered into therapy within standard oncohematology practice. ICI has demonstrated impressive response rates as salvage therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and is now being tested as an adjunction to chemotherapy in the frontline settings. CHL exquisite sensitivity to PD-1/PD-L1 axis inhibition relies on a particular biological background. By contrast, non-Hodgkin lymphomas (NHL) have demonstrated heterogeneous response rates using ICI. These observations highlight discrepancies between various types of lymphomas in terms of genetic alterations, immune microenvironment interactions, and disease phenotype. This review aims to focus on cHL immune escape mechanisms, focusing on cHL biological sensitivity to PD-1 blockade. We will summarize the available data issued from clinical trials on ICI in cHL and its safety profile. Going beyond the current use of monoclonal antibodies (mAb) targeting immune checkpoints in clinical practice, we will offer an overview of new combinatory therapeutic perspectives where cHL immunotherapy may be considered.
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/06/2019 11:25
Dernière modification de la notice
15/01/2021 8:10
Données d'usage